Design Therapeutics (DSGN) Competitors $3.97 -0.38 (-8.74%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$3.98 +0.00 (+0.13%) As of 08/7/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN vs. LENZ, TRVI, SNDX, URGN, NUVB, SION, MRSN, PROK, CRMD, and XERSShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include LENZ Therapeutics (LENZ), Trevi Therapeutics (TRVI), Syndax Pharmaceuticals (SNDX), Urogen Pharma (URGN), Nuvation Bio (NUVB), Sionna Therapeutics (SION), Mersana Therapeutics (MRSN), ProKidney (PROK), CorMedix (CRMD), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Its Competitors LENZ Therapeutics Trevi Therapeutics Syndax Pharmaceuticals Urogen Pharma Nuvation Bio Sionna Therapeutics Mersana Therapeutics ProKidney CorMedix Xeris Biopharma LENZ Therapeutics (NASDAQ:LENZ) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Does the media refer more to LENZ or DSGN? In the previous week, LENZ Therapeutics had 19 more articles in the media than Design Therapeutics. MarketBeat recorded 22 mentions for LENZ Therapeutics and 3 mentions for Design Therapeutics. LENZ Therapeutics' average media sentiment score of 0.68 beat Design Therapeutics' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend LENZ or DSGN? LENZ Therapeutics currently has a consensus price target of $49.60, suggesting a potential upside of 54.42%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in LENZ or DSGN? 54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 31.2% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, LENZ or DSGN? LENZ Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Is LENZ or DSGN more profitable? Design Therapeutics' return on equity of -22.85% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% Design Therapeutics N/A -22.85%-22.02% Which has better valuation & earnings, LENZ or DSGN? Design Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ Therapeutics$5M183.23-$49.77M-$1.90-16.91Design TherapeuticsN/AN/A-$49.59M-$0.99-4.01 SummaryDesign Therapeutics beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$246.95M$2.98B$5.42B$9.56BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-4.0117.9729.9025.14Price / SalesN/A177.57372.1776.15Price / CashN/A41.8335.9458.58Price / Book0.937.238.105.59Net Income-$49.59M-$54.43M$3.26B$265.48M7 Day Performance3.93%0.22%0.65%1.22%1 Month Performance9.07%5.59%2.43%0.39%1 Year Performance-2.22%9.98%27.70%23.47% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.2195 of 5 stars$3.97-8.7%N/A-2.7%$246.95MN/A-4.0140News CoverageEarnings ReportLENZLENZ Therapeutics1.6787 of 5 stars$31.53+0.1%$48.60+54.1%+38.5%$883.77MN/A-17.74110Upcoming EarningsGap UpTRVITrevi Therapeutics3.1738 of 5 stars$7.51-1.6%$20.88+177.8%+181.9%$877.94MN/A-16.6320Earnings ReportSNDXSyndax Pharmaceuticals4.2182 of 5 stars$10.19+6.5%$34.10+234.7%-34.8%$873.41M$23.68M-2.63110Earnings ReportAnalyst ForecastAnalyst RevisionURGNUrogen Pharma4.6782 of 5 stars$18.96+0.3%$32.86+73.3%+28.5%$872.21M$90.40M-5.94200Trending NewsEarnings ReportAnalyst ForecastGap DownNUVBNuvation Bio2.0264 of 5 stars$2.48-2.9%$7.17+189.6%-18.5%$842.15M$10.96M-1.0560News CoverageSIONSionna TherapeuticsN/A$19.05-4.0%$38.50+102.1%N/A$840.49MN/A0.0035Positive NewsLockup ExpirationMRSNMersana Therapeutics3.8963 of 5 stars$6.68-2.2%$130.00+1,846.1%-81.9%$832.53M$40.50M-11.32150Upcoming EarningsPROKProKidney3.3328 of 5 stars$2.74-11.0%$6.25+128.1%+40.4%$803.46M$80K-4.573Gap UpCRMDCorMedix2.6977 of 5 stars$11.86-1.0%$17.14+44.6%+174.4%$802.31M$43.47M53.7830News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastXERSXeris Biopharma3.0452 of 5 stars$5.10+0.5%$6.25+22.7%+209.9%$798.32M$203.07M-17.02290News CoverageEarnings ReportGap Up Related Companies and Tools Related Companies LENZ Alternatives TRVI Alternatives SNDX Alternatives URGN Alternatives NUVB Alternatives SION Alternatives MRSN Alternatives PROK Alternatives CRMD Alternatives XERS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DSGN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DSGN Stock Alerts